Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM. Wolfe AR, et al. Among authors: abushahin l. Clin Cancer Res. 2021 Jan 15;27(2):554-565. doi: 10.1158/1078-0432.CCR-20-1422. Epub 2020 Oct 21. Clin Cancer Res. 2021. PMID: 33087331 Free PMC article.
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Wolfe AR, et al. Among authors: abushahin l. Cancer Med. 2020 Jul;9(13):4711-4723. doi: 10.1002/cam4.3075. Epub 2020 May 16. Cancer Med. 2020. PMID: 32415696 Free PMC article.
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK, Perry JB, Abdul-Rahim O, Frankel AE, Cameron D, Taylor W, Rocconi RP, Abushahin L, Nelson C, Singh AP, Khushman M. Patel GK, et al. Among authors: abushahin l. J Cancer Res Ther. 2020 Jul-Sep;16(4):950-954. doi: 10.4103/jcrt.JCRT_729_18. J Cancer Res Ther. 2020. PMID: 32930150 Free article. Review.
18 results